The Promise of Cord Blood Stem Cell Research
Billions of dollars are invested in cord blood stem cell research to further explore the lifesaving and life-improving benefits of CD34+ stem cells. To date, these stem cells have proven capable of treating around 80 potentially life-threatening diseases and conditions, including various cancers and immune system disorders.
Ongoing research is aimed at discovering new stem cell applications that can treat other debilitating ailments that presently have no adequate cures. These include diabetes, Alzheimer’s disease, Parkinson’s disease, and spinal cord injuries among many others. It’s possible that research may one day capitalize on the regenerative potential of CD34+ stem cells to treat these diseases and conditions. And that possibility only gives expecting parents more reason to consider cord blood banking as a viable option for preserving their family’s future health.
LifebankUSA®, a leading cord blood bank owned by multinational biopharmaceutical company Celgene, recognizes the value of cord blood stem cell research and remains committed to staying at the forefront of stem cell research and development. Its commitment has made it the first and only bank to collect and preserve CD34+ stem cells from two distinct sources: cord blood and the placenta. Placenta-Cord banking collects more CD34+ stem cells than cord blood banking, and more stem cells can increase or improve a family’s future treatment options.
admin @ June 20, 2009